Avacta Group plc

128 articles with Avacta Group plc

• Avacta Announces Successful Completion of Fourth Dose Escalation in AVA6000 Phase 1 Clinical Study

  1/17/2023

  Avacta Group plc, a life sciences company developing innovative, targeted oncology drugs and powerful diagnostics announces that AVA6000 continues to show a very favourable safety profile in the fourth dose cohort of the ALS-6000-101 dose escalation phase 1 clinical trial.

• Avacta Announces AVA6000 Receives Orphan Drug Designation From the US Food and Drug Administration

  9/5/2022

  Avacta Group plc, a clinical stage oncology drug company and developer of powerful diagnostics based on its innovative Affimer® and pre|CISION™ platforms, announces that the US Food and Drug Administration has granted Orphan Drug Designation to the company’s lead pre|CISION drug candidate, AVA6000, for treatment of soft tissue sarcoma.

• Avacta Announces Phase I Clinical Study of AVA6000 to Advance to the Fourth Cohort

  9/1/2022

  Avacta Group plc announces that the first-in-human Phase I trial of AVA6000 Pro-doxorubicin will advance to the fourth dose cohort of patients following a positive review of the safety and tolerability data from the dosing of the third cohort.

• LG Chem Renews License Triggering Payment to Avacta

  6/30/2022

  Avacta Group plc is pleased to announce that LG Chem Life Sciences, the life sciences division of the South Korean LG Group, has exercised its renewal option as part of the ongoing collaboration with Avacta, triggering a license renewal fee payment to Avacta of $2 million.

• Avacta Announces Second Dose Escalation in the Phase I Clinical Study of AVA6000 Pro-doxorubicin

  6/29/2022

  Avacta Group plc announces that the first-in-human Phase I trial of AVA6000 Pro-doxorubicin will advance to the third dose cohort following a positive review of the safety data from the dosing of the second cohort.

• 

  Global Roundup: Prota's Immunotherapy Shows Success Against Peanut Allergy

  5/19/2022

  In a Phase IIb study, data showed that Prota Therapeutics' oral immunotherapy led to 51% of children reaching clinical remission of their peanut allergy compared to placebo. See inside for this and more!

• AffyXell Expands its Strategic Partnership With GenScript ProBio

  5/16/2022

  AffyXell, Avacta’s joint venture with Daewoong Pharmaceutical, expands its manufacturing partnership with GenScript ProBio for cell therapies.

• 

  Global Roundup: Medtronic Kicks Off Aortic Stenosis Study in Japan

  5/12/2022

  Biopharma and life sciences organizations from across the globe provide updates on their businesses and pipelines.

• Avacta Announces AffyXell Joint Venture Milestone and Increased Equity Stake

  4/13/2022

  Avacta Group plc is pleased to announce that a milestone equity payment has been triggered resulting in an increase in Avacta’s shareholding in AffyXell Therapeutics, a joint venture between Avacta and Daewoong Pharmaceutical in South Korea.

• 

  BioSpace Movers & Shakers, March 25

  3/25/2022

  Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.

• Avacta Appoints Dr Christina Coughlin as Non-Executive Director

  3/21/2022

  Avacta Group plc announces the appointment of Christina Coughlin, M.D., Ph.D., as Non-executive Director to the Board with immediate effect.

• Avacta Announces Dose Escalation in the Phase I Clinical Study of AVA6000 Pro-doxorubicin

  2/3/2022

  Avacta Group plc announces that the first-in-human Phase I trial of AVA6000 Pro-doxorubicin will advance to the next dose cohort following a positive review of the safety data from the dosing of the first cohort.

• 

  Global Roundup: UCB Snaps Up Rare Disease Company Zogenix

  1/20/2022

  Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines.

• Avacta Selects Second pre|CISION™ Pro-drug Candidate for Development

  1/18/2022

  Avacta Group plc, a clinical stage biopharmaceutical company developing innovative cancer therapies and powerful diagnostics based on its proprietary Affimer® and pre|CISION™ platforms announces that the next pre|CISION™ drug candidate, AVA3996, has been selected for pre-clinical development with a view to a first-in-human Phase I clinical trial beginning in the second half of 2023.

• 

  Global Roundup: Medtronic Acquires Affera, Inc to Expand Cardiac Ablation Line

  1/13/2022

  Biopharma and life sciences companies from across the globe provide updates to their businesses and pipelines.

• Avacta Announces AffiDX® SARS-CoV-2 Antigen Lateral Flow Test Receives CE Mark for Consumer Self-Testing

  12/22/2021

  Avacta Group plc, a clinical stage biopharmaceutical company developing innovative cancer therapies and powerful diagnostics based on its proprietary Affimer® and pre|CISION™ platforms, announces that the AffiDX® SARS-CoV-2 antigen lateral flow test has received a CE mark for use as a consumer self-test in the UK and EU.

• 

  Global Roundup: Aussie Biopharma Raises $25 Million to Expand in US

  12/16/2021

  Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines.

• Avacta Announces AffiDx® SARS-CoV-2 Antigen Lateral Flow Test Detects the Omicron Variant

  12/15/2021

  Avacta Group plc, a clinical stage biopharmaceutical company developing innovative cancer therapies and powerful diagnostics based on its proprietary Affimer® and pre|CISION™ platforms is pleased to announce that the AffiDX® antigen lateral flow test has been shown to detect the Omicron variant of the SARS-CoV-2 virus in clinical samples.

• Avacta Announces FDA Approval of its Investigational New Drug (IND) Application for AVA6000

  11/29/2021

  Avacta Group plc, a clinical stage biopharmaceutical company developing innovative cancer therapies and powerful diagnostics based on its proprietary Affimer® and pre|CISION™ platforms, is pleased to announce that the US Food and Drug Administration has approved its Investigational New Drug application for AVA6000.

• Avacta Group plc: Achievement of Pre-clinical Development Milestone in LG Chem Life Sciences Partnership

  9/29/2021

  Avacta Group plc is pleased to announce that a pre-clinical development milestone has been achieved in the multi-target therapeutics development partnership with LG Chem Life Sciences, the life sciences division of the South Korean LG Group, triggering an undisclosed milestone payment.